Condition: Atrial Fibrillation Paroxysmal · Cardiac Ablation · Cardiac Arrhythmia · Sponsor: Pulse Biosciences, Inc.
The objective of this study is to demonstrate the safety and effectiveness of the CellFX nano-second Pulsed Field Ablation (nsPFA) Cardiac Catheter Ablation System in treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation (AF).
This description comes directly from the study's public registry record.
Micki Weisman · 510-906-4649 · micki.weisman@pulsebiosciences.com
William A. Knape · 510-906-4649 · bknape@pulsebiosciences.com
Always discuss trial participation with your own doctor first.
| Na Homolce Hospital | Prague, Roentgenova, Czechia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07018596